Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplontersen in Chinese Participants With Transthyretin Amyloid Cardiomyopathy
NCT06194825Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Primary completion
- May 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 3 trial of eplontersen in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by AstraZeneca. Started Dec 2023; status: active, not recruiting.
02
Drugs
eplontersen
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT06194825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06194825.